Phase 3 Ovarian Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person is willing to give written, signed, and dated consent to take part in the study.
- The person is female and aged 18 or older.
- The person has been diagnosed, confirmed by laboratory testing of tissue or cell samples, with a specific type of ovarian, fallopian tube, or primary peritoneal cancer called high-grade serous epithelial carcinoma (certain other cancer types are not included — confirm with trial site).
- The person has cancer that has stopped responding to platinum-based chemotherapy, either by getting worse within 6 months of the last platinum treatment, or by not responding or getting worse while still receiving platinum-based treatment, and where single-agent paclitaxel is considered a suitable treatment option by the treating doctor.
- The person has received at least one previous platinum-based chemotherapy treatment (such as cisplatin or carboplatin) for their ovarian, fallopian tube, or primary peritoneal cancer.
- The person has at least one area of cancer that can be measured using standard imaging criteria (RECIST v1.1).
- The person has a general health and activity level rated at 0 or 1 on a standard medical scale (ECOG), meaning they are either fully active or have some limits but are up and about more than half the day.
- The person's heart pumping function (left ventricular ejection fraction) is at least 50%, confirmed by a heart ultrasound (echocardiogram).
- The person has recovered from side effects of previous cancer treatments, so that any remaining side effects are either at a mild or baseline level, not clinically significant, stable with supportive care, or not considered a safety risk by the treating doctor.
- In the treating doctor's opinion, the person is expected to live for at least 6 months.
- The person is not pregnant and not breastfeeding, and either is not of childbearing potential, or agrees to use a highly effective form of contraception (with less than 1% chance of failure per year) for at least 6 months after the last dose of the study treatment.
- If the person is of childbearing potential, they agree not to donate or freeze eggs for future reproduction during the contraception period, and agree to seek advice about egg donation and freezing.
- If the person is of childbearing potential, they must have a negative blood pregnancy test at the screening stage and a negative urine pregnancy test within 24 hours before the first dose of study treatment (if the urine test result is unclear, a blood test is required).
- The person has adequate bone marrow, kidney, and liver function (confirm specific values with trial site).
- For people with a documented BRCA gene mutation (inherited or acquired) or HRD status: prior treatment with a PARP inhibitor is required, unless the treating doctor determines the person was not suitable for that treatment due to side effects or intolerances, or if that treatment is not locally approved or available.
- For people with documented high levels of folate receptor alpha: prior treatment with mirvetuximab soravtansine is required, unless the treating doctor determines the person was not suitable for that treatment due to side effects or intolerances, or if that treatment is not locally approved or available.
- The person's cancer has been confirmed by imaging scans to have gotten worse during or after their most recent cancer treatment (biochemical changes alone are not enough).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have previously received paclitaxel while their cancer was platinum-resistant (this does not apply to people who received paclitaxel as part of their first-line or platinum-sensitive treatment).
- People who are candidates for surgery to remove tumours, or whose chemotherapy is planned to shrink a tumour to make surgery possible, even if the goal is palliative.
- People who are planned to receive a PARP inhibitor at the same time as the study treatment, based on their BRCA or HRD status.
- People who are currently taking certain medications known to strongly affect how the body processes drugs (known as strong CYP3A4 inducers or inhibitors, strong CYP2C8 inhibitors, or strong inducers — confirm specific medications with trial site).
- People who are planned to receive bevacizumab at the same time as the study treatment (people who have received bevacizumab in the past for ovarian cancer may still be eligible).
- People who have had maintenance therapy such as bevacizumab or PARP inhibitors — this is counted as part of the previous line of treatment, not as a separate treatment line (confirm with trial site how this affects eligibility).
- People who have had significant heart problems in the past 6 months, including unstable angina, heart attack, severe uncontrolled irregular heartbeat, significant disease of the sac around the heart, or signs of reduced blood supply to the heart on an ECG.
- People who have abnormal heart conduction (such as bundle branch block or heart block), unless that condition has been stable.
- People with a history of heart disease rated as Class 2 or higher on the NYHA classification scale (a standard medical measure of how much heart disease limits daily activities).
- People who have had a stroke, mini-stroke (TIA), or a symptomatic blood clot in the lungs.
- People with uncontrolled diabetes (defined as HbA1c of 8% or higher) or who have an active infection currently requiring treatment with systemic medication.
- People with a history of drug or alcohol misuse within the past year before screening, or who test positive for alcohol or certain drugs (including barbiturates, opiates, cocaine, cannabinoids, amphetamines, or benzodiazepines) at screening.
- People who have active cancer that has spread to the brain or the lining of the brain and spinal cord (carcinomatous meningitis is always excluded; previously treated and stable brain metastases may be considered — confirm with trial site).
- People who have taken another experimental drug or participated in another drug research study within 30 days before the first dose of the study treatment.
- People who already have nerve damage (motor or sensory) rated at Grade 2 or higher on a standard medical scale (NCI CTCAE v5.0).
- People with a history of significant liver or kidney problems, or significant vascular, lung, digestive, hormonal, neurological, blood, joint, psychiatric, or metabolic conditions that, in the treating doctor's opinion, could increase risk or affect the quality of study data.
- People who are unwilling or unable to follow the study requirements.
- People who have had another cancer (such as lymphoma, leukaemia, or other malignancies) within the past 5 years, except for certain skin cancers that have been fully removed with no sign of spread for at least 3 years, cervical carcinoma in situ, or cancers considered cured with very low risk of return.
- People who have had a known serious allergic reaction to the study drug or any of its ingredients.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If this is close to home
This page includes language about advanced illness, prognosis, or palliative care, because that is how the trial's eligibility criteria are written. Seeing it set out plainly can land hard, whether it is about you or about someone you are caring for. You do not have to be at a crisis point to talk to someone.
- Griefline — grief and loss counselling, 9am to 6pm weekdays and midday to 6pm weekends (AEST/AEDT): 1300 845 745
- Carer Gateway — practical and emotional support if you are caring for someone, 8am to 5pm weekdays: 1800 422 737
- Canteen — for 12 to 25 year olds affected by cancer, their own or a family member's: 1800 945 215
- Palliative Care Australia — directory of palliative care services near you: palliativecare.org.au
- Lifeline — 24/7, for any kind of distress, at any hour the services above are closed: 13 11 14
Palliative care is not the same as giving up on treatment, and it is not only for the last weeks of life. It is symptom and comfort care that can run alongside active treatment, including a clinical trial.
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of support and crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention.
Voxsanity is not a counselling or medical service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
Confirmed Objective Response Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.